Format

Send to

Choose Destination
Complement Ther Med. 2018 Oct;40:83-88. doi: 10.1016/j.ctim.2018.07.015. Epub 2018 Aug 3.

Safety and efficacy of Melissa officinalis (lemon balm) on ApoA-I, Apo B, lipid ratio and ICAM-1 in type 2 diabetes patients: A randomized, double-blinded clinical trial.

Author information

1
Research center for prevention of cardiovascular disease, Institute of Endocrinology & metabolism, Iran university of medical sciences, Tehran, Iran; Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
2
Research center for prevention of cardiovascular disease, Institute of Endocrinology & metabolism, Iran university of medical sciences, Tehran, Iran; Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran. Electronic address: shidfar.f@iums.ac.ir.
3
Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
4
Research center for prevention of cardiovascular disease, Institute of Endocrinology & metabolism, Iran university of medical sciences, Tehran, Iran.
5
Department of Statistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
6
Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, Iran.
7
Iranian Diabetes Association, Tehran, Iran.
8
Worcester Memorial Hospital, University of Massachusetts, Worcester, U.S.A.
9
Department of Applied Chemistry, School of Pharmaceutical Chemistry, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran.

Abstract

BACKGROUND:

The purpose of this study was to investigate the safety and effects of Melissa officinalis, a good source of bioactive components, on apolipoprotein (Apo)B, Apo A-I, and their ratio, lipids ratios and intercellular adhesion molecule-1(ICAM-1) in patients with type 2 diabetes.

METHODS:

For the present randomized, double-blinded, placebo-controlled clinical trial, 70 type 2 diabetic patients aged 20-65 years old were randomly assigned to receive hydroalcoholic extract of M. officinalis (HEMO) (700 mg/d) or placebo twice-daily for 12 weeks.

RESULTS:

There were significant differences in serum Apo A-I, TC/ HDL-c and LDL-c/ HDL-c between the two groups at the end of the study (p < 0.05), but we did not show significant differences in the values for Apo B, Apo B/Apo A-I, TG/HDL-c, ICAM-1 and liver enzymes include AST, ALT, and ALP between the study groups. Although both groups showed a significant reduction in ICAM-1, AST and, ALP (p < 0.05), no significant differences in ICAM-1, AST and, ALP were observed. At end, in M. officinalis group, there was a significant increase in Apo A-I (p = 0.003) and significant reduction in TG/HDL-c (p = 0.05) compared with initial values, as well as in placebo group, there was a significant rising in Apo B/Apo A-I (p = 0.02) and significant reduction in Apo A-I (p = 0.001) compared with baseline values.

CONCLUSIONS:

M. officinalis is safe and effective in improvement of Apo A-I, Apo B/Apo A-I, and lipids ratios as key factors promoting cardiovascular disease (CVD) in type II diabetic patients.

KEYWORDS:

Cardiovascular disease; Diabetes; Dyslipidemia; Lemon balm; Melissa officinalis

PMID:
30219475
DOI:
10.1016/j.ctim.2018.07.015
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center